Loading
A phase 3 trial of 64Cu-SAR-bisPSMA in prostate cancer, run by Clarity Pharmaceuticals Ltd, now recruiting.
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy is a phase 3 interventional study registered as NCT06056830 by Clarity Pharmaceuticals Ltd, with 383 participants planned, started 2023-12-21 and due to reach its primary completion in 2026-09. Interventions recorded: 64Cu-SAR-bisPSMA.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Clarity Pharmaceuticals, Prostate cancer and the tag pipeline.
Shares Clarity Pharmaceuticals, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/